These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 1361570)

  • 21. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
    Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
    J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
    Moore AE; Cicchetti F; Hennen J; Isacson O
    Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist.
    Rënyi L; Evenden JL; Fowler CJ; Jerning E; Kelder D; Lake-Bakaar D; Larsson LG; Mohell N; Sällemark M; Ross SB
    J Pharmacol Exp Ther; 2001 Dec; 299(3):883-93. PubMed ID: 11714872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: longevity of agonistic effects.
    Farley CM; Baella SA; Wacan JJ; Crawford CA; McDougall SA
    Brain Res; 2006 Dec; 1124(1):37-44. PubMed ID: 17070785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
    Imperato A; Tanda G; Frau R; Di Chiara G
    J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
    Beninger RJ; Mazurski EJ; Hoffman DC
    Pol J Pharmacol Pharm; 1991; 43(6):507-28. PubMed ID: 1687945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopaminergic and serotonergic autoreceptor stimulation effects are equivalent and additive in the suppression of spontaneous and cocaine induced locomotor activity.
    Carey RJ; DePalma G; Damianopoulos E; Hopkins A; Shanahan A; Müller CP; Huston JP
    Brain Res; 2004 Sep; 1019(1-2):134-43. PubMed ID: 15306247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
    Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In the search for a novel class of antipsychotic drugs: preclinical pharmacology of FG5803, a 1-piperazinecarboxamide derivative.
    Björk A; Christensson E; Albinsson A; Gustafsson B; Pettersson E; Pettersson G; Svartengren J; Andersson G
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1338-47. PubMed ID: 7996444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FCE 23884, substrate-dependent interaction with the dopaminergic system. II. Preclinical biochemical studies.
    Carfagna N; Caccia C; Mantegani S; Cavanus S; Fornaretto MG; Buonamici M; Rossi AC; Roncucci R; Fariello RG
    J Pharmacol Exp Ther; 1991 Oct; 259(1):356-64. PubMed ID: 1681088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.
    Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA
    Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.